Business
RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference\nPR Newswire\nVANCOUVER, May 21, 2015\n\n\n\nClinical trial at the University of British Columbia now recruiting patients\n\n\n\nVANCOUVER, May 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today an upcoming poster presentation at the International Society for Cellular Therapy (ISCT) on RepliCel's autologous cell treatment for chronic Achilles tendinosis currently in a Phase 1/2 clinical trial.  The presentation, taking place on May 29th from 5:30 PM to 7:00 PM local time, will review RepliCel's RCT-01 product isolated from specific cells located in the outer sheath of the hair follicle which are highly expressive of type 1 collagen, critical to the regeneration of tendon tissue.  Pre-clinical work showed a similar protein expression profile between non-bulbar dermal sheath (NBDS) cells which constitute RCT-01 and both tendon derived cells and dermal fibroblasts in terms of their ability to produce tendon-related proteins under ex vivo mechanical force (stretching).  Other data to be presented includes safety data from animal studies demonstrating NBDS cells were well-tolerated, did not form tumors or migrate to secondary sites.\n\n\"Based on our animal studies and predicate clinical trials done by collaborators using dermal fibroblasts for tendinosis,\" stated RepliCel's Director of Research and Development and poster co-author, Dr. Hisae Nakamura, \"we believe delivering collagen producing cells directly to the site of injury will address the underlying cause of tendinosis which will be superior to currently available treatments.\"\n\nRepliCel is now actively...